Invasive Breast Cancer Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Effect of Vandetanib on Cellular Markers of Proliferation and Apoptosis in Invasive Breast Cancer
Verified date | October 2021 |
Source | University of Iowa |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this project is to examine whether treatment with vandetanib has an effect on the tumor cells in breast cancer by examining tissue markers.
Status | Terminated |
Enrollment | 12 |
Est. completion date | December 21, 2018 |
Est. primary completion date | December 21, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Patients with core breast biopsy that, on pathology review, demonstrates invasive breast cancer and are determined to need surgical excision of the lesion. All subtypes of invasive breast cancer will be enrolled. Core biopsy specimens of enrolled patients will be stained for RET by immunohistochemistry and scored, however, patients will not be excluded according to RET expression. - Female gender - Age >/= 18 years of age - ECOG performance status </= 2 - Life expectancy of greater than 6 months - Ability and willingness to provide informed consent to participate in study Exclusion Criteria: - Prolonged QT interval (QTc > 480 milliseconds) on screening EKG or congenital long QT syndrome - Any concomitant medications that are known to be associated with Torsades de Pointes or QT elongation (see appendix 2). - Hypertension not controlled by medical therapy (systolic BP greater than 160 millimeters of mercury [mmHg] or diastolic blood pressure great than 100 mmHg). - Patients taking metformin or digoxin. - History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation controlled by medication are permitted. - Significant cardiac event (e.g., myocardial infarction), superior vena cava syndrome, New York Heart Association (NYHA) classification of heart disease =2 within 12 weeks, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia. - Serum calcium or magnesium outside the institutional range of normal. - Serum Potassium < 4.0 mmol/L or above 5.0 mmol/L - Creatinine clearance < 50 ml/min - PT > 12 seconds or PTT > 31 seconds - Platelet count of < 100,000 - Serum bilirubin greater than 1.5 mg/dl - Alanine aminotransferase (ALT) > 50 U/L, aspartate aminotransferase (AST) > 65 U/L, or alkaline phosphatase (ALP) > 250 U/L - Any cytotoxic treatments, such as neoadjuvant chemotherapy, planned before subsequent surgical procedure. - Previous exposure to Vandetanib - Previous enrollment or randomization in this study - Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and staff at UIHC). - Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin. - Patients who have received prior surgical site radiation. - Patients on CYP3A4 inhibitors or inducers (see appendix 1). - Inability to test core biopsy for study markers - Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential.) |
Country | Name | City | State |
---|---|---|---|
United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
Lead Sponsor | Collaborator |
---|---|
Ronald Weigel | AstraZeneca |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Percent Change From Baseline in RET Expression Observed 2 Weeks Post-treatment | Results will be stratified by RET gene expression, a negative prognostic indicator in breast cancer, to demonstrate that RET is a marker of response. | 2 weeks | |
Primary | Percent Change From Baseline in Ki-67 Cells Observed 2 Weeks Post-treatment | Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for Ki-67. | 2 weeks | |
Secondary | Percent Change From Baseline in TUNEL Observed 2 Weeks Post-treatment | Pre- and post-treatment samples will be assessed by immunohistochemistry for positivity for TUNEL. | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03595592 -
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
|
Phase 3 | |
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Recruiting |
NCT06158217 -
Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
|
||
Active, not recruiting |
NCT04448886 -
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
Phase 2 | |
Completed |
NCT02773784 -
Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
|
||
Recruiting |
NCT01509781 -
Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study
|
Phase 3 | |
Completed |
NCT04478669 -
Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
|
||
Recruiting |
NCT04553770 -
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04677816 -
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
|
Phase 2 | |
Completed |
NCT00507611 -
Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients
|
N/A | |
Completed |
NCT00581750 -
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
|
||
Completed |
NCT03304171 -
Overall Diet Quality and Breast Cancer Risk
|
N/A | |
Completed |
NCT03709186 -
Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
|
||
Terminated |
NCT03361800 -
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
|
Early Phase 1 | |
Recruiting |
NCT04648904 -
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
|
Early Phase 1 | |
Recruiting |
NCT06328465 -
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
|
N/A | |
Active, not recruiting |
NCT03109522 -
Axillary Reverse Mapping (ARM) Technique
|
N/A | |
Recruiting |
NCT03987555 -
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
|
||
Recruiting |
NCT03497702 -
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05795101 -
TRUDI: TDXD+Durva in HER2+/Low IBC
|
Phase 2 |